The World Factbook CIA Home CIA Home About CIA Careers Offices of CIA News & Information Library TEEN?s Page Contact CIA CENTRAL INTELLIGENCE AGENCY

         

This page was last updated on 31 May, 2007


Map of Algeria




Reimbursement for liver elastography:
Definition Field Listing
Nonalcoholic fatty liver disease (NAFLD) fibrosis score is based on analytes that are supposedly individually useful for evaluating patients with liver disease. The test includes ALT, albumin, aspartate aminotransferase (AST) glucose and platelet count. Age and body mass index (BMI) are also used to calculate the fibrosis score. Hepatotoxic drugs should be used with caution in TEENren with chronic HCV after assessment of potential risk versus benefit of treatment. Use of corticosteroids, cytotoxic chemotherapy, or therapeutic doses of acetaminophen are not contraindicated in TEENren with chronic HCV. In North America, there are more than 1000 FibroScan systems. We're growing fast! c See ribavirin dosing table for recommended weight-based dosages. The FibroScan 430 Mini+ offers mobility with the same experience and consistent results that you have come to expect from the FibroScan502 Touch and FibroScan 530 Compact systems. In TEENren with advanced fibrosis from chronic HCV, medications that are known to accelerate hepatic fibrosis (eg, methotrexate) should be avoided if possible. Similarly, abstinence from alcohol use is strongly advised to minimize disease progression. Although corticosteroids and other immunosuppressants may enhance HCV replication, they are not contraindicated in TEENren with HCV and should be prescribed for appropriate indications based on overall risk vs benefit. Of note, icteric flares of HCV—as reported in TEENren and adults with chronic HBV—have not been reported in TEENren receiving organ transplants or cytotoxic chemotherapy. Although underlying liver disease is a risk factor for development of sinusoidal obstruction syndrome following bone marrow transplantation, the presence of HCV infection should not delay this therapy. In the VCTE assessment, a controlled 50 Hz frequency shear wave is mechanically induced. The propagation speed of the shear wave is measured with pulse echo ultrasound. Liver stiffness is calculated using the Young's Modulus formula. Scientific validation establishes that high shear wave speed correlates to high liver stiffness. During the VCTE measurement, ultrasound attenuation rate of the liver is concurrently measured. Liver ultrasound attenuation rate, known as CAP, can provide additional information to aid in the management of liver disease. Repetitive testing by HCV RNA is not recommended. Arena U, Lupsor Platon M, Stasi C, Moscarella S, Assarat A, Bedogni G, Piazzolla V, et al. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology 2013;58:65-72. By Kimberley in forum Medical Coding General Discussion. Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for patients with genotype 4, 5, or 6 who are treatment-naive or treatment-experienced b without cirrhosis or with compensated cirrhosis a. By Kimberley in forum Medical Coding General Discussion. Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for patients with genotype 1 who are treatment-experienced b with compensated cirrhosis a. to our educational webinar program today and stay up to date on the latest trends and practices in managing liver health. Suzuki et al (2005) stated that "use of an accurate serum marker for severe hepatic fibrosis may also improve accuracy of non-invasive diagnostic models. Hyaluronic acid, a serum marker for severe hepatic fibrosis, has been reported to have a high diagnostic performance in assessing the severity of hepatic fibrosis in patients with alcoholic liver disease. In this issue, a non-invasive diagnostic model including hyaluronic acid was shown to have excellent performance in excluding the presence of medium to large esophageal varices in severe alcohol abusers. Based on current evidence, the strategy of using a non-invasive diagnostic model together with a serum marker for severe hepatic fibrosis may improve cost-benefit in the prevention of variceal hemorrhage among patients with alcoholic liver disease. The independent verification of such diagnostic models is needed". As birth to an HCV-infected mother is a known risk for infection, such offspring should be evaluated and tested for HCV. The rate of mother-to-TEEN transmission (MTCT) of HCV infection is approximately 5%, although rates are higher among women with inadequately controlled HIV coinfection, and women with higher HCV-RNA levels, or viral loads (>6 log IU/mL) ( Benova, 2014 ); ( Delotte, 2014 ); ( Cottrell, 2013 ). Identifying, following, and treating exposed TEENren is recommended. The basis for evaluation early in life is HCV-RNA testing, as maternal antibodies and consequently anti-HCV assay positivity may persist for 18 months. About 25% to 50% of infected infants spontaneously resolve HCV infection (loss of previously detectable HCV RNA) by 3 years of age ( EPHCVN, 2005 ); ( Mast, 2005 ). Testing with an HCV-RNA assay can be considered in the first year of life, but the optimal timing of such a test is unknown. Nourani and Pockros (2007) noted that biochemical markers are a potentially useful alternative to liver biopsy in patients with chronic hepatitis C aged 65 years and older. Furthermore, Rossi et al (2007) stated that an obstacle to widespread adoption of serum marker models (e.g., FibroSpect) for assessing liver fibrosis has been the lack of uniform performance indicators, such as diagnostic odds ratios and likelihood ratios. At present, serum marker models are not considered sufficiently reliable to replace liver biopsy in patients with chronic liver disease. Operator shall be duly trained and certified by Echosens or its local representative. The present document is not intended to provide user training. The FibroTest (Biopredictive, Houilles, France) and the ActiTest (Biopredictive, Houilles, France), marketed in the United States as the HCV-FibroSure Test (LabCorp, Burlington, NC) (also known as HCV-FibroSure, ASH FibroSure, NASH FibroSure) are serum biochemical tests for the assessment of fibrosis and necroinflammatory activity, respectively. The HCV-FibroSure Test includes the following five markers, as well as age and gender: alpha2-macroglobulin, haptoglobin, gamma-glutamyl transpeptidase (GGT), total bilirubin, apolipoprotein A1, plus alanine aminotransferase (ALT). These measurements are applied to an algorithm, combined with an individual's age and sex, to determine liver fibrosis severity. In addition, ASH FibroSure and NASH FibroSure purportedly provide markers for steatosis, alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH) as well as for liver fibrosis. To remain well, untreated TEENren with chronic hepatitis C are encouraged to maintain a healthy body weight due to the known deleterious effects of insulin resistance on fibrosis progression with HCV infection. Other commonly used medications, such as antimicrobial agents, antiepileptics, and cardiovascular agents, should be dosed per standard recommendations. However, NSAIDs and aspirin should be avoided, if possible, in TEENren with cirrhosis and esophageal varices due to concerns of gastrointestinal bleeding and nephrotoxicity. Acetaminophen is a safe and effective analgesic for TEENren with chronic HCV infection when dosed per package insert recommendations. Be a part of an industry leading organization that drives the business side of healthcare. In prior years, ultrasound elastography was reported using category III add-on code 0346T Ultrasound, elastography (List separately in addition to code for primary procedure), which was reported in addition to other radiology procedures (e.g., 76705). The physician charging for test interpretation and reporting will bill 91200-26 which is 0.40 RVU. Coverage and payment for FibroScan examination may vary by commerical payers. With the 2019 CPT codebook still a few weeks away, there's news of three new category I CPT codes to report ultrasound elastography (USE), which will be added to the Radiology Section. Liver elastography, mechanically induced shear wave (e.g. vibration), without imaging, with interpretation and report: CPT Code 91200 for 2019. Use 2019 I-10 Codes to Stop Human Trafficking. FibroScan Testing is Covered Under Category I CPT Code 91200. Question: What is the appropriate code to report an ultrasound (liver) elastography when it was not preceded by an abdominal ultrasound?. Echosens maintains a Reimbursement Hotline at 866-905-4837, option number 4. John Verhovshek, MA, CPC, is a contributing editor at AAPC. He has been covering medical coding and billing, healthcare policy, and the business of medicine since 1999. He is an alumnus of York College of Pennsylvania and Clemson University. Physician offices performing the FibroScan examination should bill 91200. Coverage and payment of a FibroScan examination may vary by commercial payers. parenchyma (i.e., the functional parts of a body organ). As a contributor you will produce quality content for the business of healthcare, taking the Knowledge Center forward with your knowhow and expertise. Earn CEUs and the respect of your peers. an add-on code,for each additional target lesion (reported a maximum of two units per session). Click here for instructions on how to enable JavaScript in your browser. Q3. How do hospital physicians bill for reviewing and reporting the FibroScan examination? Q1. Is there a CPT code for the FibroScan examination? Q1. Is there a CPT code for the FibroScan examination? Bookmark Thanks for bookmarking this page! The page you bookmarked will be added to the "my reading list" feed on "My ACR". Yes, category 1 CPT code 91200 is specific to the FibroScan examination. FibroScan Testing is Covered Under Category I CPT Code 91200. * CMS Physician Fee Schedule CY2019 Final Rule 1693-F. Conversion Factor 36. 0391. Proposed Rule for the 2019 Quality Payment Program. New codes (7698x-+7698x) will describe ultrasound elastography of:. In North America, more than 20 sales rep are available for your FibroScan system purchase. Engineered with Smart Tools to support consistency, irrespective of operator and across most patient morphologies. to our educational webinar program today and stay up to date on the latest trends and practices in managing liver health. Video of AASLD 2018 Update: Advancing Role of NITs in Liver Disease. In North America, there are more than 1000 FibroScan systems. We're growing fast! Echosens North America 950 Winter Street Waltham, MA 02451 USA. Webinar: The Role of Elastography in Chronic Liver Disease: The AGA Guidelines. Echosens is now your direct partner in the United States. Using patented Vibration Controlled Transient Elastography (VCTE ), the FibroScan 502 Touch is the first noninvasive device indicated for use as an aid in the clinical management of patients with liver disease. AASLD 2018 Update: Advancing Role of NITs in Liver Disease. Echosens is committed to providing healthcare professionals with the latest developments in understanding liver disease. Our on demand clinical webinar library features recordings from some of the most prominent thinkers in the industry covering a wide array of liver health related topics. is your innovation partner for non-invasive liver disease diagnostics. Video of Webinar: The Role of Elastography in Chronic Liver Disease: The AGA Guidelines. Visit our Video Library for more Webinars and Videos. The FibroScan 430 Mini+ offers mobility with the same experience and consistent results that you have come to expect from the FibroScan502 Touch and FibroScan 530 Compact systems. The FibroScan 530 Compact offers the same dual function capabilities and examination experience as the FibroScan 502 Touch. The NEW platform that will allow you to customize your marketing materials and promote your Fibroscan services!.